Kurzweil Scorecard: The Bridge Arrived. It Just Wasn’t Called Biotechnology.

In January 2026, the FDA cleared the first human trial of a cellular rejuvenation therapy built on partial epigenetic reprogramming — the closest thing yet to the “second bridge” Ray Kurzweil sketched in 2005. Eighteen patients. Glaucoma and ischemic optic neuropathy. A single dose into the eye.

That is the entire human-scale beachhead for the biotechnology Kurzweil promised would meet us before the 2030s.

Meanwhile, the intervention that has actually moved a measurable biological-age needle across a randomized human cohort this decade is a GLP-1 receptor agonist originally designed for diabetes.

Kurzweil’s longevity thesis is being tested in real time. The verdict so far is strange — closer to right than the skeptics admit, and much weirder than he predicted.

The predictions

Three claims define Kurzweil’s “Ich bin ein Singularitarian” longevity argument. They are stacked, each leaning on the next.

The base claim is that “existing knowledge can already be aggressively applied to dramatically slow aging processes so people remain in vital health until more radical therapies arrive” (The Singularity Is Near, ch. “Ich bin ein Singularitarian”). This is the first bridge — supplements, diet, surveillance, what Kurzweil and Terry Grossman codified in their 2009 book Transcend.

The middle claim, dated to the 2030s, is that “radical life extension can be achieved through a sequence in which today’s knowledge bridges to biotechnology, which then bridges to nanotechnology” (same chapter). Three bridges, sequential.

And the load-bearing claim, untethered to a specific year, is that “people alive today have the means to live long enough to benefit from successive life-extension technologies and thereby potentially live indefinitely.” Cross the bridges fast enough and aging stops compounding.

In The Singularity Is Nearer (2024), Kurzweil restated the milestone explicitly: “by around 2030, the most diligent and informed people will reach longevity escape velocity — a tipping point at which we can add more than a year to our remaining life expectancy for each calendar year that passes. The sands of time will start running in rather than out.” In October 2025 at MIT, he revised the year to “roughly 2032.” For Kurzweil personally — born 1948, now 78 — a two-year slip is not nothing.

Where we actually are

The first bridge — supplements — has been quietly demoted.

Kurzweil’s own first bridge is built on lifestyle and supplementation. The most generous reading of 2020s evidence is that supplement-based aging interventions have not produced a measurable population effect. The less generous reading is that they have been overtaken by a competing class of drugs nobody at the AGE 2005 conference would have nominated.

A 2025 randomized, double-blind, placebo-controlled trial of semaglutide in adults with HIV-associated lipohypertrophy reported a 3-to-5-year reduction in epigenetic age across the PCGrimAge and PhenoAge clocks. The signal was consistent, the trial was controlled, and the effect size is larger than any supplement-arm study has ever produced in humans. A 2025 Lancet Diabetes & Endocrinology meta-analysis across more than 85,000 GLP-1-treated participants found a 16% reduction in kidney failure and 22% slowing of filtration decline — the first pharmacologic intervention with a measurable signal on what aging researchers call organ-level decline.

The Salk Institute’s Juan Carlos Izpisua Belmonte — the same researcher who proved cyclic OSKM expression rejuvenates mouse tissue — is now running Altos Labs, which closed a $76M Series B-1 extension in May 2025 and hired Joan Mannick as Chief Medical Officer to push toward human trials. The bridge is being built. It is just not the bridge Kurzweil’s 2005 footnotes pointed to.

US 11,963,957, granted April 2024, claims methods for treating cardiovascular disease by selectively eliminating senescent cells with senolytic agents — exactly the kind of “remove damaged cells” intervention Kurzweil predicted. US 12,576,155, granted March 2026, describes senolytic prodrugs activated by SA-β-gal, a senescence-specific enzyme, so the cytotoxic payload is unmasked only inside senescent cells. The chemistry is elegant. The clinical signal is not yet there.

The Mayo Clinic Phase 2 trial of dasatinib plus quercetin in older women with osteoporosis — the only senolytic combination demonstrated to actually clear senescent cells in humans — failed to show a statistically significant difference across the full treatment group when results were reported in 2024. The published trial count globally is 9, with only 2 controlled. By contrast, semaglutide has crossed 85,000 participants in mortality-tracked trials.

The second bridge — biotechnology — has been crossed by one foot, into the eye.

On January 28, 2026, the FDA cleared Life Biosciences’ Investigational New Drug application for ER-100, a partial epigenetic reprogramming therapy delivering OCT4, SOX2, and KLF4 — the three Yamanaka factors minus c-Myc to reduce tumor risk. The Phase 1 study (NCT07290244, n=18) began recruiting in March 2026 for patients with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy.

This is the first human trial of cellular reprogramming for any indication. It is not a trial for aging. It is a trial for two specific optic nerve diseases where mouse studies showed retinal ganglion cells could be rejuvenated by transient OSK expression delivered via AAV.

The supporting science is real. US 11,754,551, granted September 2023, claims methods of identifying transcriptional and epigenetic age-related markers and reprogramming cellular age by modulating them. The 2024 Science Translational Medicine paper from Belmonte’s Altos group (DOI: 10.1126/scitranslmed.adg1777, 37 citations) showed that AAV delivery of Cdkn2a-promoted OSK extended lifespan in naturally aged wild-type mice without altering tumor incidence — a critical safety signal. A separate 2024 paper in Cellular Reprogramming (DOI: 10.1089/cell.2023.0072, 56 citations) showed gene-therapy-mediated partial reprogramming extended lifespan and reversed age-related changes in aged mice.

But the literature on partial reprogramming in aging contexts peaked at 54 papers in 2022 and has not accelerated since. The 220-citation 2022 Nature Aging paper showing in vivo partial reprogramming alters age-associated molecular changes during physiological aging is still the reference. The clinical-stage company count is one. Altos Labs, despite its size, has not filed an IND for an aging indication. Its lead program is ex vivo: rejuvenating kidneys before transplantation, not rejuvenating people.

The third bridge — medical nanorobots — does not exist.

Kurzweil writes in The Singularity Is Nearer that “the 2030s will bring another health revolution, which my book on health (coauthored with Terry Grossman, MD) calls the third bridge to radical life extension: medical nanorobots. This intervention will vastly extend the immune system.” The patent literature contains zero granted patents for an autonomous in vivo medical nanorobot that meets the specification — small enough to circulate, smart enough to identify pathogens or senescent cells, safe enough for in-human use. Theranostic nanoparticles for targeted drug delivery exist. Programmable lipid nanoparticles for mRNA delivery exist. They are not what Kurzweil meant. The functional gap between LNP delivery vehicles and circulating immune-augmenting nanorobots is roughly the gap between a paper airplane and a fighter jet.

The load-bearing claim — longevity escape velocity by 2030 — has slipped to 2032 by Kurzweil’s own admission.

US life expectancy at birth in 2024 was 79.0 years, up 0.6 years from 78.4 in 2023, according to the CDC’s NCHS January 2026 data brief. That recovery is the strongest single-year gain since the post-Spanish-flu era. But the gain is recovery from COVID excess mortality and from peak overdose deaths in 2022, not exponential progress in aging biology. Pre-pandemic 2019 life expectancy was 78.9. We are now 0.1 years above the prior peak.

Adding a year of life expectancy per calendar year is roughly 50× the current population rate. There is no demographic signal that this is happening.

Bryan Johnson, the unofficial human canary for Kurzweil’s first bridge, reports a slowed aging rate of 0.69 — eight months of biological age for every twelve calendar months. The claim is anecdotal, n=1, and the protocol is expensive. It is also the most aggressive personal application of Kurzweil’s first-bridge logic that exists, and it produces a benefit much smaller than the population-scale “1 year per year” tipping point.

The scorecard

What Kurzweil missed (and what he nailed)

He nailed the destination: cellular reprogramming and senescent-cell clearance are real, in human trials, and producing biological effects. He nailed the framework: aging as a software problem in biology that can be patched. He nailed the timeline at the field level — partial reprogramming was a 2006 lab curiosity and is a 2026 cleared IND.

He missed the path. Kurzweil’s 2005 model assumed a clean handoff: supplements buy time, biotech arrives on schedule, nanotech follows. The 2020s ran a different program. The first bridge got partially dismantled — the most biologically active “first bridge” intervention is now a class of injectable peptide hormones unrelated to the vitamin shelf — and the second bridge is wider than expected in literature and narrower than expected in clinic.

The pattern is one we have seen across other Kurzweil predictions: directionally correct, mechanistically wrong, timeline-optimistic on translation. The biology moves at exponential rates; the FDA and the safety dossiers move at linear ones. Eighteen patients in a Phase 1 in 2026 is what real “second bridge” deployment looks like — not the broad population intervention his curves implied.

If escape velocity arrives, it is now most likely to arrive through a side door Kurzweil did not name: GLP-1 metabolic drugs as the new first bridge, partial reprogramming as a narrow-indication second bridge, and a third bridge that probably will not look like Drexler-style nanorobots at all.

Method note

Numbers in this post come from US patent and pre-grant search across 9.3M documents (filtered to granted patents where noted), 357M scientific works in OpenAlex (filtered to ≥20–30 citations to keep the literature signal honest), and 541K ClinicalTrials.gov studies. Population life-expectancy figures are from the CDC NCHS January 2026 data brief. Quotes from Kurzweil are taken from The Singularity Is Near (2005) and The Singularity Is Nearer (2024), and from his October 2025 MIT talk as reported in MIT News.